オプションチェーンは、BioNexus Gene Labの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、BioNexus Gene Labの市場センチメントを評価します。.

BioNexus Gene Lab (NASDAQ:BGLC) 株価情報, オプションチェーン

BioNexus Gene Lab

BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.

BioNexus Gene Lab Corp

Barrington Research analyst Michael Petusky maintains US Physical Therapy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>) with a Outperform and maintains $98 price target.

News

Price Target

Analyst Ratings

USPH

Barrington Research Maintains Outperform on US Physical Therapy, Maintains $98 Price Target

COYA

Coya Therapeutics On Jun. 30 Resubmitted Investigational New Drug Application For COYA 302 In ALS That Includes Requested Data Due To FDA; Upon Acceptance, Co. Plans To Initiate Phase 2 Study

Well-established executive with over 20 years of experience building and leading commercial teams across diverse therapeutic markets and geographies
Career focused on driving business growth and developing an integrated commercial strategy to deliver results
ISELIN, N.J., July 01, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Rx-ipauQbHp0RYHUWHsNH_Slrg1M7dQAfLScDZO2S22swiv5-OqiF0_q0AiTcN2lOaoGCUbZjjMBJzSLaTOKOSv9PQ5g03wc_wSuz1921F0-o-1KSMFMZabQXdm_4ULo">Outlook Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTLK#NASDAQ">OTLK</a>), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the appointment of Bob Jahr as Chief Executive Officer (CEO). Mr. Jahr has also been appointed to the Outlook Therapeutics Board of Directors. Lawrence A. Kenyon, who has served as Outlook Therapeutics' Chief Financial Officer (CFO) and interim CEO, will continue serving as CFO and as a member of the Board of Directors.

Management

OTLK

Outlook Therapeutics Appoints Bob Jahr As CEO

WIIM

WOLF

Wolfspeed shares are trading higher after the company initiated its pre-packaged restructuring process.

ECD Automotive Design (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECDA#NASDAQ">ECDA</a>), the industry leader in reimagined British classics and bespoke performance vehicles, is proud to announce two major victories on the national automotive stage. The company's highly acclaimed Jaguar E-Type "The Wellesley Commission" earned First Place at the Larz Anderson Auto Museum's British Car Day, while its first custom Ford Mustang build, Project Ghost '67, took home Best of Class at the 2025 Route 66 Road Fest in Tulsa, Oklahoma.

ECDA

ECD Automotive Design Wins National Awards For Custom Jaguar E-Type And Ford Mustang Builds

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

MARA

MARA Targeting 75 Exahash By End Of 2025, Representing 40% Growth Over 2024; Says 211 Blocks Won In June, Increased BTC Holdings To 49,940 BTC

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said Rio Tinto (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIO#NYSE">RIO</a>) has a big yield and recommended buying the stock. &#8220;I believe in the minerals. I think you're fine,&#8221; he added.
As per the recent news, Rio Tinto and Hancock Prospecting announced on June 24 a joint investment of $1.61 billion to develop the Hope Downs 2 iron ore project in Western Australia&#8217;s Pilbara region. A 50-50 investment will drive a significant expansion of the long-standing Hope Downs Joint Venture between the two companies.
Cramer said TG Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>) is a buy.
Supporting his view, the company, on May 5, reported first-quarter sales of $120.86 million, up from $63.47 million a year ago, beating the consensus of $118.43 million.
Michael S. Weiss, TG Therapeutics Chairman and Chief Executive Officer, stated, "2025 is off to a strong start, and I'm incredibly proud of the progress made thus far. Our performance in the first quarter, including BRIUMVI's $119.7 million in U.S. net sales, demonstrates the growing confidence in our treatment and the increasing adoption by healthcare providers.&#8221;
&#8220;This momentum, combined with the positive feedback we're hearing from both patients and clinicians, reinforces our belief that we can achieve our long-term goal of BRIUMVI becoming the number one prescribed anti-CD20 treatment based on dynamic market share," he added.
Price Action:
<ul class="wp-block-list">
<li>Rio Tinto shares fell 0.7% to settle at $58.33 on Monday.</li>
<li>TG Therapeutics shares declined 2% to close at $35.99.</li>
</ul>
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/46169288/5-stocks-in-the-spotlight-wall-streets-most-accurate-analysts-weigh-in">5 Stocks In The Spotlight: Wall Street&#8217;s Most Accurate Analysts Weigh In</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Media

Trading Ideas

TGTX

Cramer Backs This Mining Giant After $1.6B Bet

CLRO

ClearOne shares are trading higher. The company announced it will issue a one-time special stock dividend on July 18.

Melius Research analyst Scott Davis initiates coverage on Carrier Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>) with a Hold rating and announces Price Target of $90.

Initiation

CARR

Melius Research Initiates Coverage On Carrier Global with Hold Rating, Announces Price Target of $90

Envoy Medical&#xAE; Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCH#NASDAQ">COCH</a>) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced the issuance of three new patents, further strengthening its intellectual property portfolio in Australia.
The Australian Patent Office has issued the following three patents to Envoy Medical Corporation:
<ul>
<li>Australian Patent No. 2021391396 on April 24, 2025. The title of the patent is Implantable Cochlear Implant Stimulation Calibration. This patent relates to cochlear implant systems having a testing circuit that determines an amount of current provided by a source element of the system. The source element can be adjusted to calibrate an amount of current provided by the system during stimulation.</li>
<li>Australian Patent No. 2021390456, on May 8, 2025. The title of the patent is Combination Hearing Aid and Cochlear Implant System. This patent relates to cochlear implant systems that update operations to compensate for the presence of an external hearing aid to improve simultaneous operation of the cochlear implant system and the external hearing aid and prevent the hearing aid from skewing sounds perceived by a wearer.</li>
<li>Australian Patent No. 2022227534, on May 22, 2025. The title of the patent is Recharge System for Implantable Battery. This patent relates to systems and methods for predicting a cumulative thermal dose associated with charging an implanted rechargeable battery and monitoring charging parameters such as temperature to minimize battery charging time while maintaining safe thermal conditions.</li>
</ul>

Global

Envoy Medical, Inc. - Class A Common Stock

COCH

Envoy Medical Secures 3 New Australian Patents For Advanced Cochlear Implant Technologies

TD SYNNEX Acquires Apptium, Terms Not Disclosed

AREB

American Rebel Holdings Announces Retail Authorization Of Its American Rebel Light Beer At 62 Minuteman Food Mart Locations In North And South Caroline

Ramaco Resources, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/METC#NASDAQ">METC</a>, METCB))) ("Ramaco Resources" or the "Company") is pleased to announce that the Fluor Corporation ("Fluor") will deliver its full Preliminary Economic Assessment ("PEA") of Ramaco's Brook Mine on or before July 8, 2025. Today, Fluor has provided Ramaco with the summary results of that report which the Company is disclosing in a separate letter to Shareholders from Ramaco's Chairman and Chief Executive Randall Atkins.
The Fluor PEA states that the project is both commercially and technologically feasible. This report marks a significant step forward and builds on Fluor's earlier interim preliminary techno-economic analysis. The Brook Mine holds what is believed to be the nation's largest&nbsp;unconventional deposit of rare earth elements and critical minerals sourced from coal and carbonaceous ore.

METC

Fluor Confirms $1.2B Value For Ramaco's Brook Mine, Validating Feasibility Of Nation's Largest Unconventional Rare Earth Deposit

UBS analyst Michael Goldsmith initiates coverage on Kite Realty Gr Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRG#NYSE">KRG</a>) with a Neutral rating and announces Price Target of $24.

UBS Initiates Coverage On Kite Realty Gr Trust with Neutral Rating, Announces Price Target of $24

Dyne Therapeutics shares are trading lower after the company announced a $200 million public offering.

Wolfe Research analyst Andy Chen initiates coverage on Verona Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNA#NASDAQ">VRNA</a>) with a Outperform rating and announces Price Target of $170.

VRNA

Wolfe Research Initiates Coverage On Verona Pharma with Outperform Rating, Announces Price Target of $170

ATAI

Atai Life Sciences shares are trading higher after the company announced it raised $50 million via a private placement.

Richtech Robotics Added To Russell 2000 And Russell 3000 Indices

Contracts

MNTS

Momentus Signs Contract With Orbit Fab To Provide Hosted Payload Services For On-Orbit Demonstration Of Podracer

The Brook Mine will also be first new coal mine in Wyoming in over 50 years
RANCHESTER, Wyo., July 1, 2025 /PRNewswire/ -- Ramaco Resources, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/METC#NASDAQ">METC</a>, METCB, ", Ramaco", or the ", Company", ))) and Ramaco Rare Earth, LLC will host a landmark ribbon cutting and groundbreaking ceremony on Friday, July 11, to commemorate the opening of the Brook Mine Carbon Ore Rare Earth project. It will be the first new rare earth mine in the United States in more than 70 years and first new coal mine in Wyoming in over 50 years.
The event, themed "American Independence: A Rare Earth Revolution," will take place at Ramaco's iCAM Technology Center in Ranchester, Wyoming, and is scheduled to feature remarks from national and state leaders. This includes U.S. Secretary of Energy Chris Wright, Wyoming Governor Mark Gordon, U.S. Senators John Barrasso and Cynthia Lummis, U.S. Representative Harriet Hageman and former U.S. Senator and Ramaco Board member Joe Manchin.

Ramaco To Open First New U.S. Rare Earth Mine In 70 Years, First New Wyoming Coal Mine In Over 50 Years

Financing

Press Releases

BioNexus Gene Lab Corp. Completes Strategic RM 1 Million Investment in Ascension Innovation Sdn Bhd

BioNexus Gene Lab Corp. Announces Successful Securities Commission of Malaysia (MyCIF) Co-Investment in Ascension Innovation Sdn Bhd

General

BioNexus Gene Lab Corp Announces New Business Developments for Subsidiary Chemrex with Investment in High-Quality Color Paste Production

BioNexus Gene Lab Corp. Signs Strategic Partnership MOU with Shenzhen Rongguang Group to Advance Cancer Screening, Precision Medicine, and Preventative Healthcare Solutions

BioNexus Gene Lab Corp. Signs Strategic Outsourcing Agreement with VITARRAY Global Pte. Ltd.

BioNexus Gene Lab Corporation announces entry into Biogas Sector via Teaming Agreement with Protech Builders Sdn. Bhd.

BioNexus Gene Lab Corp. Announces Board Approval of Ethereum Treasury Strategy and Release of Strategic Whitepaper

BioNexus Gene Lab Corp and ML Tech Partner to Enhance Ethereum-focused Treasury Strategy

BioNexus Gene Lab Corp. Files 2024 Annual Report Highlighting Strategic Innovation, Operational Resilience, and Growth Trajectory

BioNexus Gene Lab Corp. Regains Nasdaq Compliance, Signaling Strategic Stability and Growth Readiness

Comments

BioNexus Gene Lab

BioNexus Gene Lab (BGLC) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル